Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.

Abstract

A 55-year-old male patient with hepatitis B-related liver cirrhosis was found to have advanced hepatocellular carcinoma. His AFP was initially 9828 microg/L and rapidly dropped to 5597 microg/L in ten days after oral sorafenib treatment. However, he developed acute renal failure, hyperkalemia, and hyperuricemia 30 d after receiving the sorafenib treatment. Tumor lysis syndrome was suspected and intensive hemodialysis was performed. Despite intensive hemodialysis and other supportive therapy, he developed multiple organ failure (liver, renal, and respiratory failure) and metabolic acidosis. The patient expired 13 d after admission.

• Authors: Wu-Shiung Huang, Chang-Hsu Yang
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 15 Issue 35 Pg. 4464-6 (Sep 21 2009) ISSN: 2219-2840 [Electronic] United States
• PMID: 19764104 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzenesulfonates
• Phenylurea Compounds
• Protein Kinase Inhibitors
• Pyridines
• Niacinamide
• Sorafenib

Topics

• Benzenesulfonates (adverse effects)
• Carcinoma, Hepatocellular (drug therapy, pathology)
• Fatal Outcome
• Humans
• Liver Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Niacinamide (analogs & derivatives)
• Phenylurea Compounds
• Protein Kinase Inhibitors (adverse effects)
• Pyridines (adverse effects)
• Sorafenib
• Tumor Lysis Syndrome (drug therapy, etiology)